Effect of Essential Phospholipids and Statin on Non Alcoholic Fatty Liver Disease in Rats Induced Periodontitis *
@inproceedings{Ahmed2017EffectOE, title={Effect of Essential Phospholipids and Statin on Non Alcoholic Fatty Liver Disease in Rats Induced Periodontitis *}, author={Nevien Mahmoud Ahmed and Ahmed Sh. Hashem}, year={2017} }
NAFLD is the most common form of chronic liver disease, it is the hepatic manifestation of metabolic syndrome. Periodontal disease may helpfully increase the risk of progression from NAFL to NASH. Effective strategies are needed to treat NAFLD and prevent progression to NASH so we conducted this study to investigate the efficacy of EPL and statin on biochemical parameters and histo-pathological finding in rats with NAFLD and periodontitis. Methods: 35 Male rats were divided into 5 groups, group…
References
SHOWING 1-10 OF 30 REFERENCES
Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease
- Medicine, BiologyBMC Gastroenterology
- 2012
Infection with high-virulence P. gingivalis might be an additional risk factor for the development/progression of NAFLD/NASH and non-surgical periodontal treatments carried out for 3 months ameliorated the liver function parameters, such as the serum levels of AST and ALT.
Hepatic lipid metabolism and non-alcoholic fatty liver disease.
- Medicine, BiologyNutrition, metabolism, and cardiovascular diseases : NMCD
- 2009
Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease
- MedicineScandinavian journal of clinical and laboratory investigation
- 2010
Serum osteoprotegerin concentrations are reduced in patients with the more severe forms of NAFLD and may serve as a noninvasive biomarker to identify patients with NASH.
Therapeutic efficacy of polyunsaturated phosphatidylcholine on fatty liver disease
- Medicine
- 2010
Polyunsaturated Phosphatidylcholine improves the liver function and liver histopathology in patients with fatty liver and is effective and safe in the treatment of fatty liver disease.
Treatment of non-alcoholic fatty liver disease: can we already face the epidemic?
- MedicineActa gastro-enterologica Belgica
- 2013
Evidence is accumulating that NAFLD is an independent risk factor for cardiovascular diseases, and some pharmacological agents show promising results, although on the basis of recent clinical trials no firm conclusions can be drawn.
Dental infection of Porphyromonas gingivalis exacerbates high fat diet-induced steatohepatitis in mice
- Medicine, BiologyJournal of Gastroenterology
- 2012
It is demonstrated for the first time that P.g. existed in the liver of NASH patients with advanced fibrosis and may play an important role in NASH progression through upregulation of the LPS-TLR2 pathway and activation of inflammasomes.
Activity of essential phospholipids (EPL) from soybean in liver diseases.
- Biology, MedicinePharmacological reports : PR
- 2011
Experimental periodontitis promotes transient vascular inflammation and endothelial dysfunction.
- Medicine, BiologyArchives of oral biology
- 2013
The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
- Medicine, BiologyJournal of hepatology
- 2005